Skip to content

Study on early intervention of patients of asymptomatic hyperuricemia

Study on early intervention of patients of asymptomatic hyperuricemia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000038575
Enrollment
Unknown
Registered
2020-09-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asymptomatic hyperuricemia

Interventions

experimental group:Fuling-Zexie Decoction
control group:placebo

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged between 18-75 years; 2. Patients who meet the diagnosis of asymptomatic hyperuricemia; 3. Patients who meet the dampness syndrome inclusion criteria; 4. Patients who sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Secondary hyperuricemia population, for instance, secondary to malignancy, hemopathy, nephropathy, chronic intoxication; 2. History of alcoholism without abstinence in recent 3 months; 3. Had one or more attacks of gout arthritis in the past; 4. Received urate-lowing drugs or drugs that may increase serum uric acid in recent 4 weeks, such as antituberculotic drugs, low dose aspirin, Loop diuretics and thiazide diuretics and blood pressure medications containing diuretics, niacin, large dosage of vitaminC, chemotherapeutic drugs and cyclosporin; 5. Pregnancy and lactation population, or has possibility of conception but failure to use effective contraception; 6. Alanine aminotransferase or aspartate aminotransferase or creatinine 2 times or more than the normal value; 7. Combined with serious organic lesions, mental disorders or other reasons can not cooperate with treatment; 8. Allergic or ineffective to the test drug ingredients.

Design outcomes

Primary

MeasureTime frame
the decrease in serum uric acid;

Secondary

MeasureTime frame
Chinese syndrome score;measurement of the Chinese channel and tongue diagnosis;Glomerular filtration rate;Urinary ß2 microglobulin;uric acid excretion fraction;Incidence rate of complications, such as gout, hyperlipemia, cardiovascular events, diabetes, etc.;Ultrasound of double ankles and the first metatarsophalangeal joints;blood?urine metabolite;Inflamation index: hsCRP, TNF-a, IL-6, IL-8;

Countries

China

Contacts

Public ContactXiaohog He

Guangdong provincial hospital of Chinese Medicine

1418381600@qq.com+86 13660581225

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 12, 2026